	Rating	
Note: Diagnosis of endometriosis must be substantiated by laparoscopy.		
1 Barrian Caractellar and the caractellar and the caractellar		

¹Review for entitlement to special monthly compensation under § 3.350 of this chapter.

[60 FR 19855, Apr. 21, 1995]

THE HEMIC AND LYMPHATIC SYSTEMS

§4.117 Schedule of ratings—hemic and lymphatic systems.

Rating

7700 Anemia, hypochromicmicrocytic and megaloblastic, such as iron-deficiency and pernicious anemia: Hemoglobin 5gm/100ml or less, with findings such as high output congestive heart failure or dyspnea at rest 100 Hemoglobin 7gm/100ml or less, with findings such as dyspnea on mild exertion, cardiomegaly, tachycardia (100 to 120 beats per minute) or syncope (three episodes in the last six months) 70 Hemoglobin 8gm/100ml or less, with findings such as weakness, easy fatigability, headaches, lightheadedness, or shortness of breath Hemoglobin 10gm/100ml or less with findings such as weakness, easy fatigability or headaches Hemoglobin 10gm/100ml or less, asymptomatic

Note: Evaluate complications of pernicious anemia, such as dementia or peripheral neuropathy, separately.

7702 Agranulocytosis, acute:

Note: The 100 percent rating for bone marrow transplant shall be assigned as of the date of hospital admission and shall continue with a mandatory VA examination six months following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.

7703 Leukemia:

NOTE: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no recurrence, rate on residuals.

7704 Polycythemia vera:

NOTE: Rate complications such as hypertension, gout, stroke or thrombotic disease separately.

7705 Thrombocytopenia, primary, idiopathic or immune:

Platelet count of less than 20,000, with active bleeding, requiring treatment with medication and transfusions 100 Platelet count between 20,000 and 70,000, not requiring treatment, without bleeding 70 Stable platelet count between 70,000 and 100,000, without bleeding 30 Stable platelet count of 100,000 or more, without bleeding n 7706 Splenectomy 20

Note: Rate complications such as systemic infections with encapsulated bacteria separately.

30 10

100

30 10

Rating	R	ating
7707 Spleen, injury of, healed. Rate for any residuals. 7709 Hodgkin's disease: With active disease or during a treatment phase	Note: The 100 percent rating shall contibeyond the cessation of any surgical, ration, antineoplastic chemotherapy other therapeutic procedures. Six morafter discontinuance of such treatment the appropriate disability rating shall dtermined by mandatory VA examition. Any change in evaluation by upon that or any subsequent examinates shall be subject to the provisions \$3.105(e) of this chapter. If there has an local recurrence or metastasis, raterisiduals. 7716 Aplastic anemia: Requiring bone marrow trans-	or nths ent, l be ina- ased tion of peen
§3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on	plant, or; requiring trans- fusion of platelets or red cells	
residuals. 7710 Adenitis, tuberculous, active	at least once every six weeks, or; infections recurring at	
or inactive. Rate under §§ 4.88c or 4.89 of this	least once every six weeks Requiring transfusion of plate- lets or red cells at least once	100
part, whichever is appropriate. 7714 Sickle cell anemia:	every three months, or; infec-	
With repeated painful crises, occurring in skin, joints, bones or any major organs caused by hemolysis and sickling of red blood cells, with anemia, thrombosis and infarction, with symptoms precluding even light manual labor	tions recurring at least once every three months	the con- tion rge. that
of symptomatic sickle cell trait will be forwarded to the Director, Compensation and Pension Service, for consideration	THE SKIN	
under §3.321(b)(1) of this chapter. 7715 Non-Hodgkin's lymphoma:	§4.118 Schedule of ratings—skin.	
With active disease or during a treatment phase 100		Rat- ing
•	7800 Scars, disfiguring, head, face or neck: Complete or exceptionally repugnant deformity of one side of face or marked or repugnant bilateral disfigurement. Severe, especially if producing a marked and unsightly deformity of eyelids, lips, or auricles Moderate; disfiguring	50 30 10

Slight